Metoprolol
- Generic Name
- Metoprolol
- Brand Names
- Kapspargo, Lopressor, Lopressor Hct, Toprol
- Drug Type
- Small Molecule
- Chemical Formula
- C15H25NO3
- CAS Number
- 51384-51-1
- Unique Ingredient Identifier
- GEB06NHM23
- Background
Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release. The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferre...
- Indication
Metoprolol is indicated for the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.
Some off-label uses of metoprolol include supraventricular tachycardia and thyroid storm.
...
- Associated Conditions
- Angina Pectoris, Atrial Fibrillation, Hypertension, Migraine, Myocardial Infarction, Supraventricular Tachycardia (SVT), Thyroid Crisis, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III)
- Associated Therapies
- -
Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 186
- Registration Number
- NCT01508325
- Locations
- 🇨🇳
Merck Serono Investigational Site, Changsha City, China
To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol
- Conditions
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 28
- Registration Number
- NCT01478490
- Locations
- 🇳🇱
PRA International (former Pharma Bio-Research), Zuidlaren, Netherlands
Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)
- Conditions
- Interventions
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Mikael Lantz
- Target Recruit Count
- 65
- Registration Number
- NCT01458600
- Locations
- 🇸🇪
Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden
🇸🇪Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden
🇸🇪Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy
- Conditions
- Interventions
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- University Hospital, Akershus
- Target Recruit Count
- 130
- Registration Number
- NCT01434134
- Locations
- 🇳🇴
Akershus University Hospital, Lørenskog, Norway
Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol
- Conditions
- Interventions
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 20
- Registration Number
- NCT01404767
- Locations
- 🇨🇦
University Heatlh Network, Toronto General Hopsital, Toronto, Ontario, Canada
Nebivolol and the Endothelin (ET)-1 System
- Conditions
- Interventions
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- University of Colorado, Boulder
- Target Recruit Count
- 42
- Registration Number
- NCT01395329
- Locations
- 🇺🇸
UC-Boulder Clinical and Translational Research Center, Boulder, Colorado, United States
Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)
- Conditions
- Interventions
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT01337674
Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT01330654
- Locations
- 🇺🇸
Community Regional Medical Center, Fresno, California, United States
A Study of the Effect of LY2189265 on Two Blood Pressure Drugs
- Conditions
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 51
- Registration Number
- NCT01324388
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- European Institute of Oncology
- Target Recruit Count
- 320
- Registration Number
- NCT01281787
- Locations
- 🇮🇹
European Institute of Oncology, Milan, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.